spacer
home > ict > spring 2020 > integration of cardiac endpoints
PUBLICATIONS

 

Dear guest!
To access full content of this article, please take a minute to become a member of this site. As a registered user you will be able to view all of our vast archive's material at any time. Sign up now!

       Already registered? Please sign in.

Alternatively, please use our pay-per-view service.

spacer

 
News and Press Releases

Lesaffre Acquires Recombia Biosciences, a Biotechnology Company Specialized in High-Throughput Genome Editing and Synthetic Biology

Lesaffre, a global key player in the field of fermentation for nearly 170 years, today announces the acquisition of Recombia Biosciences, a biotechnology company based in the San Francisco Bay Area and founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. The partnership marked Lesaffre’s entry into the world of Synthetic Biology, considered to be one of the largest biotechnology opportunities of this decade.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement